N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Sponsor: Mayo Clinic • ClinicalTrials.gov ID: NCT06635980

Registry updated: 2026-09-03
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This phase II trial studies how well hypofractionated radiotherapy before (preoperative) or after (postoperative) breast surgery works in treating patients with different types of non-metastatic (has not spread from original tumor site) breast cancer and to determine the outcomes and side effects of this treatment. Radiation therapy is considered an integral part of breast conserving therapy. Hypofractionated radiation therapy is a radiation treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day. This has been shown to be an effective treatment for breast cancer while reducing treatment time and decreasing side effects. Preoperative radiotherapy alone or concurrently with chemotherapy has also been tested with excellent results and with minimal toxicity. Preoperative radiation of the intact tumor with a hypofractionated regimen can potentially decrease toxicity by allowing the delivery of treatment to intact breast tissue. The potential advantages of preoperative radiation therapy include the delivery of radiation in the intact breast when radiation can be more effective as more oxygen can be available in the tissue. Furthermore, complications and cosmetic results are expected to be lower in pre-operative radiotherapy before surgery, as there have been no changes in blood supply to the breast. This lends to the possibility of using lower doses of radiotherapy to patients, and potentially better cancer associated clinical outcomes for our breast cancer patients. Undergoing hypofractionated radiation therapy before or after breast surgery may be safe and effective in treating patients with different types of non-metastatic breast cancer.

Interventions

  • Biopsy of Breast (Procedure)
    Undergo breast biopsy
  • Biospecimen Collection (Procedure)
    Undergo blood sample collection
  • Breast Surgery (Procedure)
    Undergo breast surgery
  • Chemotherapy (Drug)
    Receive SOC chemotherapy
  • Computed Tomography (Procedure)
    Undergo CT
  • Contrast Enhanced Digital Mammography (Procedure)
    Undergo CEDM
  • Hypofractionated Radiation Therapy (Radiation)
    Undergo hypofractionated radiotherapy
  • Magnetic Resonance Imaging (Procedure)
    Undergo MRI
  • Positron Emission Tomography (Procedure)
    Undergo PET
  • Survey Administration (Other)
    Ancillary studies
  • Tissue Collection (Procedure)
    Undergo tissue collection
  • Ultrasound Imaging (Procedure)
    Undergo ultrasound

Eligibility criteria

Inclusion Criteria: * Age \>= 18 years * Histological confirmation of breast cancer * Clinical stage T1-T4 N0-3 M0 * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2 * Able to and provides Institutional Review Board (IRB)-approved study specific written informed consent * Able to complete all mandatory tests listed in the trial * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * Indications for radiotherapy for breast cancer Exclusion Criteria: * Medical contraindication to receipt of radiotherapy * Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent in the judgment of the principal investigator * Active systemic lupus or scleroderma * Pregnancy * Women of childbearing potential who are unwilling to employ adequate contraception * Prior receipt of ipsilateral breast or chest wall radiation * Recurrent breast cancer

Conditions

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Breast Carcinoma Triple-Negative Breast Carcinoma

Locations

  • Mayo Clinic in Arizona — Scottsdale, Arizona, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record